{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:44:39Z","timestamp":1773233079832,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinre.2025.102702","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:29:18Z","timestamp":1759303758000},"page":"102702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a cross-species model to predict clinical outcomes based on efficacy in mouse models of non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8087-0043","authenticated-orcid":false,"given":"Haoxiang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiesen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieren","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10290","key":"10.1016\/j.clinre.2025.102702_bib0001","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clinre.2025.102702_bib0002","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.tem.2024.02.012","article-title":"Evolving liver disease insights from NAFLD to MASLD","volume":"35","author":"Fan","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.clinre.2025.102702_bib0003","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102702_bib0004","first-page":"1","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease","volume":"6","author":"Bradford","year":"2013","journal-title":"Hepat Med"},{"issue":"2","key":"10.1016\/j.clinre.2025.102702_bib0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/17460441.2020.1811674","article-title":"Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints","volume":"16","author":"Do","year":"2021","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"10.1016\/j.clinre.2025.102702_bib0007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3390\/ijms24010158","article-title":"Lessons on drug development: a literature review of challenges faced in nonalcoholic fatty liver disease (NAFLD) clinical trials","volume":"24","author":"Chen","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.clinre.2025.102702_bib0008","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/cncr.34357","article-title":"Envisioning clinical trials as complex interventions","volume":"128","author":"Stensland","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clinre.2025.102702_bib0009","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s42977-020-00050-4","article-title":"Biologia futura: animal testing in drug development-the past, the present and the future","volume":"71","author":"S\u00e1ntha","year":"2020","journal-title":"Biol Futur"},{"issue":"1","key":"10.1016\/j.clinre.2025.102702_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/jcm10010036","article-title":"In Vitro and In vivo models of non-alcoholic fatty liver disease: a critical appraisal","volume":"10","author":"Soret","year":"2020","journal-title":"J Clin Med."},{"issue":"2","key":"10.1016\/j.clinre.2025.102702_bib0011","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2025.102702_bib0012","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/clinchem\/46.12.2027","article-title":"Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests","volume":"46","author":"Dufour","year":"2000","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.clinre.2025.102702_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2024.100593","article-title":"Comparative efficacy of NAFLD therapies and biomarker associations: a meta-analysis based on liver fat content","volume":"4","author":"Zhu","year":"2024","journal-title":"Gastro Hep Adv"},{"issue":"1","key":"10.1016\/j.clinre.2025.102702_bib0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/aje\/kwr265","article-title":"Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software","volume":"175","author":"Orsini","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.clinre.2025.102702_bib0015","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270003253624","article-title":"Model appropriateness and population pharmacokinetic modeling","volume":"43","author":"Ette","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.clinre.2025.102702_bib0016","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102702_bib0017","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-016-3071-1","article-title":"Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours","volume":"78","author":"Goulooze","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102702_bib0018","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","article-title":"Extensions to the visual predictive check to facilitate model performance evaluation","volume":"35","author":"Post","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"10.1016\/j.clinre.2025.102702_bib0019","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1023\/A:1016215116835","article-title":"Population pharmacokinetic modeling: the importance of informative graphics","volume":"12","author":"Ette","year":"1995","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinre.2025.102702_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1066053","article-title":"Lingguizhugan decoction improves non-alcoholic steatohepatitis partially by modulating gut microbiota and correlated metabolites","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102702_bib0021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13020-021-00559-3","article-title":"Traditional Chinese medicine lingguizhugan decoction ameliorate HFD-induced hepatic-lipid deposition in mice by inhibiting STING-mediated inflammation in macrophages","volume":"17","author":"Cao","year":"2022","journal-title":"Chin Med"},{"issue":"19","key":"10.1016\/j.clinre.2025.102702_bib0022","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1158\/1078-0432.CCR-07-4534","article-title":"Validation of biomarker-based risk prediction models","volume":"14","author":"Taylor","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clinre.2025.102702_bib0023","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/foods12010094","article-title":"Alleviation effects of microbial metabolites from resveratrol on non-alcoholic fatty liver disease","volume":"12","author":"Guo","year":"2022","journal-title":"Foods"},{"issue":"7","key":"10.1016\/j.clinre.2025.102702_bib0024","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bph.12057","article-title":"An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK","volume":"168","author":"Kim","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinre.2025.102702_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114445","article-title":"Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models","volume":"161","author":"Kim","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinre.2025.102702_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clinre.2025.102702_bib0027","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci Rep."},{"key":"10.1016\/j.clinre.2025.102702_bib0028","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.12659\/MSM.900033","article-title":"The effect of Sitagliptin on lipid metabolism of fatty liver mice and related mechanisms","volume":"23","author":"Xu","year":"2017","journal-title":"Med Sci Monit"},{"issue":"7","key":"10.1016\/j.clinre.2025.102702_bib0029","first-page":"3705","article-title":"Global liver gene expression analysis on a Murine metabolic syndrome model treated by low-molecular-weight Lychee fruit polyphenol (Oligonol\u00ae)","volume":"36","author":"Uchiyama","year":"2016","journal-title":"Anticancer Res"},{"issue":"5\u20136","key":"10.1016\/j.clinre.2025.102702_bib0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000522117","article-title":"Docosahexaenoic acid attenuates the progression of nonalcoholic steatohepatitis by suppressing the adipocyte inflammation via the G protein-coupled receptor 120\/free fatty Acid receptor 4 pathway","volume":"107","author":"Nakamoto","year":"2022","journal-title":"Pharmacology"},{"key":"10.1016\/j.clinre.2025.102702_bib0031","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jnutbio.2017.01.011","article-title":"A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice","volume":"42","author":"Saraswathi","year":"2017","journal-title":"J Nutr Biochem"},{"issue":"2","key":"10.1016\/j.clinre.2025.102702_bib0032","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4093\/dmj.2019.0042","article-title":"Combination of probiotics and salvia miltiorrhiza polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice","volume":"44","author":"Wang","year":"2020","journal-title":"Diabetes Metab J"},{"issue":"9","key":"10.1016\/j.clinre.2025.102702_bib0033","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hep4.1107","article-title":"Role of Aramchol in steatohepatitis and fibrosis in mice","volume":"1","author":"Iruarrizaga-Lejarreta","year":"2017","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.clinre.2025.102702_bib0034","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1248\/bpb.b20-00432","article-title":"A lipid-based nanocarrier containing active vitamin D3 ameliorates NASH in mice via direct and intestine-mediated effects on liver inflammation","volume":"43","author":"Mu","year":"2020","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"10.1016\/j.clinre.2025.102702_bib0035","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00394-021-02668-z","article-title":"Effects of \u03b2-glucan, probiotics, and synbiotics on obesity-associated colitis and hepatic manifestations in C57BL\/6J mice","volume":"61","author":"Vu","year":"2022","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.clinre.2025.102702_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.788558","article-title":"Ursodeoxycholic acid treatment restores gut microbiota and alleviates liver inflammation in non-alcoholic steatohepatitic mouse model","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102702_bib0037","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbrc.2018.09.134","article-title":"Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet","volume":"505","author":"Zhu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinre.2025.102702_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102043","article-title":"Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1\/ppar\u03b3 binodal complementary modules","volume":"45","author":"Das","year":"2021","journal-title":"Redox Biol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102702_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17460441.2018.1410135","article-title":"Non-alcoholic fatty liver disease (NAFLD) models in drug discovery","volume":"13","author":"Cole","year":"2018","journal-title":"Expert Opin Drug Discov"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:19:49Z","timestamp":1773159589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125001792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2210740125001792"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102702","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a cross-species model to predict clinical outcomes based on efficacy in mouse models of non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102702"}}